PMID- 24508774
OWN - NLM
STAT- MEDLINE
DCOM- 20140613
LR  - 20211203
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1845
IP  - 2
DP  - 2014 Apr
TI  - Targeting bone metastatic cancer: Role of the mTOR pathway.
PG  - 248-54
LID - S0304-419X(14)00016-X [pii]
LID - 10.1016/j.bbcan.2014.01.009 [doi]
AB  - One of the great challenges of cancer medicine is to develop effective treatments 
      for bone metastatic cancer. Most patients with advanced solid tumors will develop 
      bone metastasis and will suffer from skeletal related events associated with this 
      disease. Although some therapies are available to manage symptoms derived from 
      bone metastases, an effective treatment has not been developed yet. The mammalian 
      target of rapamycin (mTOR) pathway regulates cell growth and survival. 
      Alterations in mTOR signaling have been associated with pathological 
      malignancies, including bone metastatic cancer. Inhibition of mTOR signaling 
      might therefore be a promising alternative for bone metastatic cancer management. 
      This review summarizes the current knowledge on mTOR pathway signaling in bone 
      tissue and provides an overview on the known effects of mTOR inhibition in bone 
      cancer, both in in vitro and in vivo models.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
FAU - Bertoldo, Francesco
AU  - Bertoldo F
AD  - Department of Medicine, Universita' di Verona, Verona, Italy.
FAU - Silvestris, Franco
AU  - Silvestris F
AD  - Department of Biomedical Sciences and Human Oncology, Section of Clinical 
      Oncology, University of Bari 'A. Moro', Bari, Italy.
FAU - Ibrahim, Toni
AU  - Ibrahim T
AD  - Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio 
      e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Cognetti, Francesco
AU  - Cognetti F
AD  - Division Oncology, Regina Elena Institute, Rome, Italy.
FAU - Generali, Daniele
AU  - Generali D
AD  - UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e 
      Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Cremona, Italy.
FAU - Ripamonti, Carla Ida
AU  - Ripamonti CI
AD  - Supportive Care in Cancer Unit, Department of Hematology and Pediatric 
      Onco-Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
FAU - Amadori, Dino
AU  - Amadori D
AD  - Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio 
      e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Colleoni, Marco Angelo
AU  - Colleoni MA
AD  - Division of Medical Senology, European Institute of Oncology, Milan, Italy.
FAU - Conte, Pierfranco
AU  - Conte P
AD  - Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
FAU - Del Mastro, Lucia
AU  - Del Mastro L
AD  - UO Sviluppo Terapie Innovative, IRCCS AOU San Martino, IST, National Institute 
      for Cancer Research, Genoa, Italy.
FAU - De Placido, Sabino
AU  - De Placido S
AD  - Department of Endocrinology and Molecular and Clinical Oncology, University of 
      Naples Federico II, Naples, Italy.
FAU - Ortega, Cinzia
AU  - Ortega C
AD  - Oncology Unit, IRCC Candiolo, Torino, Italy.
FAU - Santini, Daniele
AU  - Santini D
AD  - Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy. 
      Electronic address: d.santini@unicampus.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140205
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/*drug therapy/*genetics/pathology/secondary
MH  - Bone and Bones
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Mice
MH  - Molecular Targeted Therapy
MH  - Signal Transduction/*genetics
MH  - Sirolimus/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*genetics/metabolism
OTO - NOTNLM
OT  - Bone metastatic cancer
OT  - Cellular signaling
OT  - Everolimus
OT  - Osteoblast
OT  - Osteoclast
OT  - mTOR
EDAT- 2014/02/11 06:00
MHDA- 2014/06/15 06:00
CRDT- 2014/02/11 06:00
PHST- 2013/12/17 00:00 [received]
PHST- 2014/01/22 00:00 [revised]
PHST- 2014/01/28 00:00 [accepted]
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2014/06/15 06:00 [medline]
AID - S0304-419X(14)00016-X [pii]
AID - 10.1016/j.bbcan.2014.01.009 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. 
      Epub 2014 Feb 5.